Showing results (1421-1430 of 4,380) with videos related to
Sort By:
Pageof 438
ACS Medicinal Chemistry Letters|November 19, 2025
Design, Synthesis, and Cellular Efficacy of Inositol-Requiring Enzyme Type 1 (IRE1α) InhibitorsGiulia Murbach, Adam D Mitrevski, Patricia A Fontan, et al.ACS Medicinal Chemistry Letters|September 17, 2025
Novel Cyclic Peptides Trapping Interleukin-1β to Relieve Inflammatory and Atherosclerotic Cardiovascular DiseaseQilong Hu, Steven H LiangACS Medicinal Chemistry Letters|September 17, 2025
Glycine Betaine-Functionalized Ionic Liquids: Design of Versatile Bioplatform for Incorporating Biologically Active Moieties into CationsWitold Stachowiak, Marcin Wysocki, Lorenzo Guazzelli, et al.ACS Medicinal Chemistry Letters|September 17, 2025
Radiosynthesis and Biological Evaluation of a Small-Molecule Probe for Thyroid-Stimulating Hormone ReceptorYuanyuan Zhou, Ji Tao, Yuanpeng Jiang, et al.ACS Medicinal Chemistry Letters|September 17, 2025
Novel Pyrido[4,3‑d]pyrimidine Compounds as KRAS InhibitorsJian Rong, Steven H LiangACS Medicinal Chemistry Letters|September 17, 2025
Novel Piperidine Derivatives as NNMT Inhibitors for Treating Chronic Kidney Disease or Acute Kidney InjuryRam W SabnisACS Medicinal Chemistry Letters|September 17, 2025
Novel Non-Hallucinogenic Compounds as 5‑HT2A Agonists for Treating Mental Health Disorders, Namely Depression, Anxiety, Stress Disorders, and Eating DisordersRam W SabnisACS Medicinal Chemistry Letters|August 20, 2025
Novel Mixed Serotonin Receptor Binder Compounds as 5‑HT2C Agonists for Treating Psychotic DisordersRam W SabnisACS Medicinal Chemistry Letters|August 20, 2025
Novel Phenethylamines as 5‑HT2A Agonists for Treating Depression, Drug Addiction, Alcoholism, PTSD, and Neuropathic PainRam W SabnisPageof 438